NASDAQ:CERO CERo Therapeutics Q3 2025 Earnings Report $0.01 0.00 (0.00%) As of 09/23/2026 03:39 PM Eastern ProfileEarnings HistoryForecast CERo Therapeutics EPS ResultsActual EPS-$9.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACERo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACERo Therapeutics Announcement DetailsQuarterQ3 2025Date11/19/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsCERo Therapeutics' next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile CERo Therapeutics Earnings HeadlinesCERo Therapeutics Holdings Secures New Consolidated Financing FacilityAugust 31, 2026 | tipranks.comSRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of ...August 31, 2026 | markets.businessinsider.comIran War TRUTH: What Two Congressmen Led Me ToTwo private meetings with U.S. Congressmen on March 2nd, three days after the first missiles fell, sent one analyst down an unexpected research trail. The investigation uncovered a coordinated operation, a shadow group running it, and one company sitting at the center of it all.September 24 at 1:00 AM | Behind the Markets (Ad)CERo Therapeutics Expands Convertible Debt Financing ArrangementJuly 17, 2026 | tipranks.comNasdaq, Inc.: Delisting of Securities from The Nasdaq Stock MarketJuly 11, 2026 | finanznachrichten.deCERo Therapeutics Holdings, Inc. Common Stock (CERO)June 25, 2026 | nasdaq.comSee More CERo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CERo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CERo Therapeutics and other key companies, straight to your email. Email Address About CERo TherapeuticsCERo Therapeutics (NASDAQ:CERO) is a clinical-stage biopharmaceutical company developing engineered T-cell therapies for cancer. The company’s technology is designed to expand the capabilities of conventional T cells by combining targeted tumor-cell recognition and killing with phagocytic activity, potentially enabling immune cells to engulf and eliminate malignant cells. CERo’s lead product candidate is CER-1236, an engineered T-cell therapy directed at CD123, a cell-surface protein expressed on several hematologic malignancies, including acute myeloid leukemia. The company has been advancing CER-1236 toward clinical development and is evaluating its potential in patients with relapsed or refractory blood cancers. Its broader research programs are focused on applying the company’s engineered-cell platform to additional oncology targets. The company was established to develop next-generation cellular immunotherapies and became publicly traded through a business combination with Phoenix Biotech Acquisition Corp. in 2024. CERo Therapeutics is focused primarily on research, development and clinical testing rather than commercial product sales, and its therapies are not yet broadly available.View CERo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
